Evidence map›Paper›PMID 40148296›Full record

ReviewCurrent pharmaceutical design2025

CRNDE, a Potential Therapeutic Target in Human Diseases.

Shiyun Zeng, Yao Xie, Yulan Shi, Fenghua Qu, Xinchen Wang, Yuting Liu, Qingqing Li, Houdong Li, Chengfu Yuan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shiyun ZengThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Yao XieThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Yulan ShiThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Fenghua QuThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Xinchen WangThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Yuting LiuThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Qingqing LiThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.
Houdong LiCollege of Traditional Chinese Medicine, China Three Gorges University & Yichang Hospital of Traditional Chinese Medicine, Yichang, 443002, China.
Chengfu YuanThird-grade Pharmacological Laboratory on Traditional Chinese Medicine, State Administration of Traditional Chinese Medicine, China Three Gorges University, Yichang, 443002, China.

Funding

innovational group project of Hubei Province Natural Science Foundation in China 2021CFA015Joint Fund Project of Hubei Province Natural Science Foundation in China 2024AFD231National Natural Science Foundation of China 82174035, 82374107, 81974528, 81773959Open Foundation for Tumor Microenvironment and Immunotherapy Key Laboratory of Hubei province in China 2023KZL01traditional Chinese Medicine Science and Technology Research and Development Special Project of Yichang public hospital reform and high-quality development demonstration project in China YWGZ24-06Yichang Medical and Health Research Project A23-1-065
6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are RNA molecules exceeding 200 nucleotides in length with minimal or no protein-coding potential. However, a large number of lncRNAs have been discovered as research has progressed, and the traditional view of these noncoding RNAs does not appear to be entirely correct. Recent research has also unveiled their significant roles in various biological processes, spotlighting lncRNAs' importance. The oncogenic lncRNA, Colorectal tumor Differentially Expressed (CRNDE), is prominently studied in cancer contexts. One study found that the modulation of CRNDE expression led to an improvement in the median survival of cancer patients, extending it from 19.2 months to 32.5 months. Nonetheless, CRNDE also exhibits deregulated expression in non-malignant diseases, influencing their pathologies and serving as a potential biomarker and therapeutic target. For example, in the context of COVID-19, with CRNDE serving as a diagnostic indicator, its diagnostic accuracy attains a value as high as 0.889. This review examines CRNDE's expression in specific human diseases, including non-cancerous and cancerous conditions, its impact on disease progression, the underlying mechanisms, and recent therapeutic approaches.

Indexed as

NeoplasmsRNA, Long NoncodingCOVID-19HumansCRNDE RNA, humanRNA, Long Noncodingbiomarkercontrol mechanismCRNDEhuman diseasesLncRNAtherapeutic target.

Identifiers

PMID40148296

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.